Fabrication of gold nanoparticle for potential application in multiple myeloma

Chitta Ranjan Patra, Rajanshu Verma, Shaji Kumar, Philip R. Greipp, Debabrata Mukhopadhyay, Priyabrata Mukherjee

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

The importance of nanotechnology in human health care is unquestionable. There is a growing interest to apply nanotechnology in cancer therapy, as an example. In this report, we have fabricated gold nanoparticle (AuNP), the delivery vehicle of interest, with an anti-cancer drug (Velcade) and a targeting agent (folic acid) for potential therapeutic application in multiple myeloma. Physico-chemical characterization of the nanoconjugates were carried out by UV-Visble spectroscopy exploiting the surface plasmon resonance band of AuNP, transmission electron microscopy (TEM) and studying release of radio-labeled tritiated folic acid (3FA) in a scintillation counter. The evidence of the attachment of velcade to AuNP was confirmed UV-Vis spectroscopy and studying the release of 3FA from gold-velcade-FA conjugates (Au-Vel-FA). Furthermore, the stability of Au-Vel-FA tested in PBS (phosphate buffer saline) by monitoring the release of 3FA suggested significant stability of the nanoconjugate. Functional activity of the nanoconjugate was tested by studying the apoptosis of different multiple myeloma cell lines by annexin/PI method. Apoptosis data suggested that Velcade retained its functional activity in Au-Vel-FA. In future, this strategy may be potentially utilized as an alternative approach for the treatment of multiple myeloma.

Original languageEnglish (US)
Pages (from-to)499-507
Number of pages9
JournalJournal of Biomedical Nanotechnology
Volume4
Issue number4
DOIs
StatePublished - Dec 1 2008

    Fingerprint

Keywords

  • Drug delivery
  • Gold nanoparticle
  • Multiple myeloma
  • Velcade

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this